{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:41:11Z","timestamp":1781188871162,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007059","name":"Palack\u00fd University","doi-asserted-by":"crossref","award":["IGA UPOL LF_2016_006"],"award-info":[{"award-number":["IGA UPOL LF_2016_006"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijantimicag.2016.12.005","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T20:17:17Z","timestamp":1486671437000},"page":"348-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Is continuous infusion of imipenem always the best choice?"],"prefix":"10.1016","volume":"49","author":[{"given":"Hana","family":"Such\u00e1nkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lip\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Urb\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3170-5831","authenticated-orcid":false,"given":"Jan","family":"Strojil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"As\u00edn-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0035","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mcp.2002.122526","article-title":"Tissue distribution of imipenem in critically ill patients","volume":"71","author":"Tegeder","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijantimicag.2012.09.007","article-title":"Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region","volume":"41","author":"Kiratisin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/dkq449","article-title":"Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients","volume":"66","author":"Roberts","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0065","series-title":"Proceedings of the 14th IEEE symposium on computer-based medical systems. CBMS 2001","first-page":"389","article-title":"An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK\/PD) population models","author":"Leary","year":"2001"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0070","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem\u2013cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0080","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.00032-15","article-title":"Achieving target voriconazole concentrations more accurately in children and adolescents","volume":"59","author":"Neely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5507\/bp.2016.014","article-title":"Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region","volume":"160","author":"Herkel","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0090","author":"European Committee on Antimicrobial Susceptibility Testing"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2016.12.005_bib0095","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1086\/653049","article-title":"Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia","volume":"51","author":"Torres","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bcp.12435","article-title":"Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens","volume":"78","author":"Couffignal","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","article-title":"Comparison of 30-min and 3-h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation","volume":"68","author":"Lee","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0110","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/jac\/dki375","article-title":"Pharmacokinetics of imipenem in healthy volunteers following administration by 2\u2009h or 0.5\u2009h infusion","volume":"56","author":"Jaruratanasirikul","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","article-title":"Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis","volume":"44","author":"Novelli","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijantimicag.2014.01.028","article-title":"Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course","volume":"43","author":"Carlier","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0125","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0130","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/AAC.38.5.931","article-title":"Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model","volume":"38","author":"Mouton","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0140","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/bcp.12901","article-title":"Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid","volume":"81","author":"Van Hasselt","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0145","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jac\/dkn543","article-title":"Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5\u2009h infusion","volume":"63","author":"Jaruratanasirikul","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2006.02.020","article-title":"Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients","volume":"28","author":"Rafati","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000107725","article-title":"Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion","volume":"53","author":"Langgartner","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijantimicag.2010.06.043","article-title":"Stability of doripenem, imipenem and meropenem at elevated room temperatures","volume":"37","author":"Keel","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijantimicag.2015.01.007","article-title":"Subtleties in practical application of prolonged infusion of \u03b2-lactam antibiotics","volume":"45","author":"De Waele","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.005_bib0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2016.03.020","article-title":"Application of pharmacodynamic profiling for the selection of optimal \u03b2-lactam regimens in a large university hospital","volume":"46","author":"Koomanachai","year":"2016","journal-title":"Int J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T15:52:54Z","timestamp":1656863574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0924857917300407"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is continuous infusion of imipenem always the best choice?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}